Novo Nordisk A/S
NVO
$54.20
-$0.0981-0.18%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.18B | 15.05B | 14.65B | 13.79B | 13.05B |
| Total Depreciation and Amortization | 1.51B | 1.16B | 936.38M | 1.02B | 1.07B |
| Total Amortization of Deferred Charges | 36.44M | 36.44M | 36.44M | 30.75M | 30.75M |
| Total Other Non-Cash Items | 3.56B | 5.43B | 3.74B | 5.57B | 2.42B |
| Change in Net Operating Assets | -3.39B | -2.69B | -1.78B | -3.20B | 165.71M |
| Cash from Operations | 17.89B | 18.98B | 17.59B | 17.21B | 16.73B |
| Capital Expenditure | -8.21B | -7.49B | -6.83B | -5.89B | -4.95B |
| Sale of Property, Plant, and Equipment | 4.50K | 4.50K | 4.50K | 147.40K | -- |
| Cash Acquisitions | -11.65B | -11.74B | -11.74B | -96.39M | -96.39M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 632.10M | -814.90M | 42.96M | -1.64B | -1.42B |
| Cash from Investing | -19.23B | -20.05B | -18.53B | -7.62B | -6.47B |
| Total Debt Issued | 117.48B | 106.75B | 79.39B | 34.63B | 34.51B |
| Total Debt Repaid | -77.85B | -18.05B | -6.34B | -6.26B | -5.99B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -11.28B | -18.73B | -20.18B | -22.45B | -26.19B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.27B | -7.27B | -6.45B | -6.45B | -6.12B |
| Other Financing Activities | 0.00 | 21.45B | 0.00 | 0.00 | 0.00 |
| Cash from Financing | -3.71B | 5.73B | 1.12B | -5.61B | -5.79B |
| Foreign Exchange rate Adjustments | -84.15M | 45.12M | 63.66M | -68.99M | 43.34M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.13B | 4.70B | 241.41M | 3.92B | 4.51B |